Claims for Patent: 12,128,083

Summary for Patent: 12,128,083

Title:	Lisinopril formulations
Abstract:	Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Inventor(s):	Gerold L. Mosher, David W. Miles
Assignee:	Azurity Pharmaceuticals Inc
Application Number:	US18/450,553
Patent Claims:	1. A stable oral liquid formulation, comprising: (i) about 1 mg/ml lisinopril or a pharmaceutically acceptable salt or solvate thereof; (ii) a preservative; (iii) a liquid vehicle, wherein the liquid vehicle comprises water; and (iv) a sweetener, wherein the sweetener comprises xylitol, mannitol, sorbitol, glycerin, maltitol, sucrose, aspartame, sucralose, saccharin, acesulfame, or a pharmaceutically acceptable salt thereof; wherein the pH of the formulation is between about 4 and about 8; wherein the formulation is stable at about 25±5° C. for at least 6 months. 2. The formulation of claim 1, wherein the lisinopril is lisinopril dihydrate. 3. The formulation of claim 1, wherein the pH is between about 4 to about 5.2. 4. The formulation of claim 1, wherein the pH is between about 5 to about 8. 5. The formulation of claim 1, wherein the pH is about 4.9. 6. The formulation of claim 1, wherein the formulation is stable at about 25±5° C. for at least 18 months. 7. The formulation of claim 1, wherein the sweetener is xylitol or sucralose. 8. The formulation of claim 1, wherein the preservative is an anti-microbial. 9. A stable oral liquid formulation, comprising: (i) about 1 mg/ml lisinopril or a pharmaceutically acceptable salt or solvate thereof; (ii) a preservative; (iii) a liquid vehicle, wherein the liquid vehicle comprises water; (iv) a sweetener, wherein the sweetener comprises xylitol, mannitol, sorbitol, glycerin, maltitol, sucrose, aspartame sucralose, saccharin, acesulfame, or a pharmaceutically acceptable salt thereof; and (v) a buffer, wherein the buffer concentration is from about 5 to about 50 nM; wherein the formulation is stable at about 25±5° C. for at least 6 months. 10. The formulation of claim 9, wherein the lisinopril is lisinopril dihydrate. 11. The formulation of claim 9, wherein the pH of the formulation is between about 4 and about 5.2. 12. The formulation of claim 9, wherein the pH is between about 5 to about 8. 13. The formulation of claim 9, wherein the formulation is stable at about 25±5° C. for at least 18 months. 14. The formulation of claim 9, wherein the sweetener is xylitol or sucralose. 15. The formulation of claim 9, wherein the buffer concentration is from about 5 to about 20 mM. 16. The formulation of claim 9, wherein the buffer comprises citric acid or a salt or a hydrate thereof. 17. The formulation of claim 9, wherein the buffer comprises phosphoric acid or salt thereof. 18. The formulation of claim 9, wherein the buffer comprises sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium gluconate, aluminum hydroxide, aluminum hydroxide/sodium bicarbonate co-precipitate, an amino acid, aluminum glycinate, citric acid, sodium citrate, sodium tartrate, sodium acetate, sodium carbonate, sodium phosphate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogenphosphate, dipotassium hydrogenphosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, or calcium bicarbonate. 19. The formulation of claim 9, wherein the preservative is an anti-microbial.